Does Amerigroup Cover Tirzepatide (Mounjaro)?

What Is Tirzepatide and Why Does It Matter for Coverage Decisions?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it under the brand name Mounjaro for type 2 diabetes in May 2022 [1]. A separate formulation, Zepbound, received FDA approval for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, in November 2023 [2].

That distinction matters enormously for Amerigroup members. Insurance carriers, including Amerigroup, code coverage by FDA-approved indication. A prescription written for type 2 diabetes (ICD-10: E11.x) follows a different coverage pathway than one written for obesity (ICD-10: E66.x). Mixing up these codes, or submitting a claim under the wrong indication, is one of the most common reasons an initial claim is rejected.

Tirzepatide's clinical profile is exceptional. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg at 40 weeks (P<0.0001) [3]. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced a mean body-weight reduction of 22.5% at 72 weeks versus 2.4% for placebo (P<0.0001) [4]. These results have driven intense patient demand and, as a consequence, tighter insurer scrutiny.

How Amerigroup Plans Are Structured

Amerigroup is a subsidiary of Elevance Health (formerly Anthem). It primarily administers Medicaid managed care plans in roughly 20 states, along with Medicare Advantage plans in select markets. The specific formulary and prior authorization criteria for tirzepatide depend heavily on which Amerigroup product a member is enrolled in.

Medicaid Managed Care (Amerigroup): State Medicaid programs set the underlying coverage rules. States vary widely. Texas Medicaid, for example, has historically required step therapy through metformin and a sulfonylurea before approving a GLP-1 or dual GIP/GLP-1 agent. Georgia Medicaid managed through Amerigroup has separate clinical criteria documents. Members should request the specific formulary for their state plan, not a generic Amerigroup document.

Medicare Advantage (Amerigroup): Part D drug coverage follows CMS guidelines. Tirzepatide for type 2 diabetes is a covered Part D drug. CMS prohibits Medicare from covering weight-loss medications, which means Zepbound remains excluded from Medicare Part D regardless of plan. The American Diabetes Association's 2024 Standards of Care in Diabetes state: "For patients with type 2 diabetes who need greater glucose lowering than is achieved with oral agents, GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred agents, particularly for those with or at high risk for cardiovascular disease, heart failure, or chronic kidney disease" [5].

Marketplace / Commercial Plans: Some Amerigroup-affiliated commercial plans exist in certain markets. These may have broader coverage than Medicaid for obesity indications, though step therapy and PA requirements still apply.

Prior Authorization Criteria Amerigroup Typically Requires

Prior authorization is essentially universal for tirzepatide under Amerigroup. The exact criteria differ by plan year and state, but a consistent set of clinical requirements appears across most Amerigroup PA documents reviewed by the HealthRX medical team.

For the type 2 diabetes indication, Amerigroup generally requires:

1. A confirmed diagnosis of type 2 diabetes (ICD-10 E11.x).
2. A baseline HbA1c of 7.0% or higher, documented within the past 3 to 6 months.
3. Documentation that the member has tried and had an inadequate response to metformin at a therapeutic dose (typically 1 to 000 mg twice daily for at least 90 days), unless metformin is contraindicated or not tolerated.
4. Many plans add a second step-therapy agent requirement, such as a sulfonylurea, SGLT-2 inhibitor, or DPP-4 inhibitor.
5. Prescriber attestation that the drug is being used for type 2 diabetes, not weight loss alone.
6. Confirmation that the member does not have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), per the FDA boxed warning [1].

For the weight management indication (Zepbound, where covered), criteria typically include BMI of 30 or higher, or 27 or higher with a comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea, plus documentation of a supervised diet and exercise program.

Authorizations, when approved, are usually granted for 6 to 12 months. Renewal requires documentation of clinical response, typically defined as a reduction in HbA1c of at least 0.5 percentage points or body-weight loss of at least 5% from baseline.

The HealthRX medical team has outlined a five-step PA submission framework that addresses the most common documentation gaps leading to denials in Amerigroup and similar Medicaid managed care plans:

Step 1, Confirm the active formulary. Request the current year's drug formulary from Amerigroup member services (call the number on the insurance card) or access it through the state Medicaid member portal. Formularies update annually on January 1.

Step 2, Gather three months of clinical records. The PA reviewer needs recent HbA1c values, the medication administration record showing prior drug trials, and a current problem list with the diabetes diagnosis.

Step 3, Complete the PA form with exact ICD-10 and NDC codes. Tirzepatide for diabetes uses a different National Drug Code (NDC) than Zepbound. Submitting the wrong NDC is a common clerical error that causes automatic denials.

Step 4, Include the prescriber letter. A brief, structured letter from the ordering clinician explaining why tirzepatide is medically necessary, why step-therapy agents were insufficient, and what the anticipated clinical benefit is, materially improves approval rates.

Step 5, Set a follow-up calendar alert for 72 hours. Most Amerigroup PA decisions are due within 72 hours for non-urgent requests (3 business days) and 24 hours for urgent requests under CMS rules. Following up proactively prevents delays.

What to Do If Amerigroup Denies Coverage

A denial is not the end of the road. Federal and state law provide formal appeal rights. Under CMS Medicaid managed care rules (42 CFR 438.402), Amerigroup must provide a written notice of adverse action with the specific clinical reason for denial and instructions for filing an internal appeal [6].

Level 1 Internal Appeal: The member or prescriber submits additional clinical documentation within the timeframe stated in the denial letter (commonly 60 days). New information, such as a specialist note from an endocrinologist or additional HbA1c data, should accompany this appeal.

Level 2 External Appeal / State Fair Hearing: If the internal appeal is denied, the member may request an independent external review or a state Medicaid fair hearing. External reviewers are required to apply evidence-based clinical criteria, not purely formulary cost criteria.

Expedited Appeal: When a standard timeline would seriously jeopardize health, the member can request an expedited decision, which CMS rules require within 72 hours [6].

A 2022 study published in JAMA Internal Medicine found that patients who appealed Part D denial decisions and provided physician-authored supporting letters had overturning rates exceeding 75% in some drug categories [7]. While that figure is not specific to tirzepatide or Amerigroup, it underscores the value of persistence and documentation quality.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm states: "Pharmacotherapy should be considered for patients with obesity or overweight with comorbidities when lifestyle interventions alone do not achieve or maintain clinically meaningful weight loss" [8]. Citing this guideline directly in an appeal letter for weight-management indications adds clinical weight to the request.

Cost Without Coverage: What Amerigroup Members Pay Out of Pocket

Without insurance coverage, tirzepatide carries a significant price. The Wholesale Acquisition Cost (WAC) for Mounjaro in 2024 is approximately $1,069.08 for a 28-day supply across all doses, according to Eli Lilly pricing data [9]. Zepbound has a similar WAC structure.

Eli Lilly offers a savings card program for commercially insured patients who meet eligibility criteria (not available to Medicaid or Medicare beneficiaries). Eligible patients may pay as little as $25 for a 1- to 3-month prescription. Medicaid and Medicare members are legally excluded from manufacturer copay cards under federal anti-kickback rules.

Compounded tirzepatide from 503B outsourcing facilities became widely available during FDA drug shortage designations. However, the FDA removed tirzepatide from its drug shortage list in October 2023 for some presentations and has continued updating shortage status since [10]. Compounded versions of brand-name drugs that are no longer in shortage may face FDA enforcement actions. Members considering compounded tirzepatide should verify current FDA shortage status and consult with their prescriber.

Patient assistance programs through Lilly Cares may offer free or reduced-cost medication for qualifying low-income patients who do not have any drug coverage at all. Income thresholds apply, and the application process requires prescriber involvement.

Amerigroup Coverage by State: Key Variations

Because Amerigroup operates as a Medicaid managed care organization (MCO) in multiple states, coverage rules are state-specific. Below are notable patterns based on publicly available state Medicaid PDLs (Preferred Drug Lists) and the HealthRX team's review of Amerigroup formulary documents.

Texas: Texas Medicaid's Vendor Drug Program publishes a PDL that Amerigroup Texas must follow. As of 2024, tirzepatide appears on the PDL with PA required and step therapy through at least one oral hypoglycemic agent. The Texas Health and Human Services Commission updates the PDL quarterly.

Georgia: Amerigroup Georgia is one of the state's CMO (Care Management Organization) plans. Georgia Medicaid requires PA for all GLP-1 and dual GIP/GLP-1 agents. The state specifies metformin step therapy and an HbA1c threshold in its published clinical criteria.

Tennessee: TennCare, Tennessee's Medicaid program, uses a Select formulary through its MCOs. Tirzepatide carries a PA requirement with similar step-therapy requirements.

Nevada: Amerigroup Nevada follows Nevada Medicaid's Uniform PDL. Coverage criteria align closely with national clinical guidelines for type 2 diabetes management.

New Jersey: NJ FamilyCare, managed in part through Amerigroup, includes tirzepatide with PA. New Jersey has shown more permissive criteria for GLP-1 class drugs relative to some Southern states.

In every state, the safest step is to call Amerigroup's pharmacy benefit line (printed on the back of the member ID card) and ask three specific questions: (1) Is tirzepatide on the formulary for my plan year? (2) What are the PA criteria? (3) Is step therapy required, and if so, which agents?

How Tirzepatide Compares to Other GLP-1 Agents in Amerigroup Formularies

Amerigroup and most Medicaid MCOs cover multiple agents in the GLP-1 and related class. Understanding where tirzepatide sits relative to alternatives helps members and prescribers anticipate the authorization pathway.

Semaglutide (Ozempic for T2D, Wegovy for obesity) is the most frequently cited comparator. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [11]. Tirzepatide 15 mg in SURMOUNT-1 produced 22.5% weight loss at 72 weeks [4], a difference that has influenced some prescribers to advocate for tirzepatide specifically.

Dulaglutide (Trulicity) and liraglutide (Victoza) are older GLP-1 receptor agonists. Both have generic or biosimilar pathways emerging, which may make them preferred first-line agents on state Medicaid PDLs before tirzepatide. If a formulary requires step therapy through a GLP-1 before approving a dual GIP/GLP-1, then a failed trial with dulaglutide or liraglutide may satisfy that requirement.

Exenatide extended-release (Bydureon BCise) is another option that appears on some Medicaid formularies at a lower tier. Prescribers who want to support tirzepatide access may prescribe an older GLP-1 first, document the therapeutic response, and then step up to tirzepatide with that documentation supporting the PA.

Cardiovascular and Renal Considerations That Strengthen PA Requests

Payers pay close attention to comorbidities when making PA decisions. Tirzepatide, like other GLP-1 class agents, has demonstrated cardiovascular and renal benefits that can be leveraged in prior authorization documentation.

The SURPASS-CVOT trial (SURPASS-4, N=2,002) showed tirzepatide reduced major adverse cardiovascular events (MACE) compared to insulin glargine in patients with type 2 diabetes and high cardiovascular risk at 104 weeks [12]. A member with established cardiovascular disease, heart failure, or chronic kidney disease has a significantly stronger clinical argument for tirzepatide specifically, rather than a less expensive alternative.

The 2024 American Diabetes Association Standards of Care designate GLP-1 receptor agonists and dual GIP/GLP-1 agents as preferred add-on therapies for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, or chronic kidney disease with high risk of progression [5]. Including this guideline citation in a PA letter, alongside the member's documented cardiovascular or renal comorbidities, gives the Amerigroup PA reviewer a clear evidence-based rationale for approval.

Practical Steps for Amerigroup Members Right Now

Getting coverage approved requires coordinated action from both the patient and the prescriber's office.

For the patient:

• Call Amerigroup member services before the prescription is sent to the pharmacy. Confirm tirzepatide's formulary status and whether a PA is on file.
• Ask the prescriber's office to use a specialty pharmacy that has an established PA workflow with Amerigroup. Large specialty pharmacies often have dedicated PA teams.
• Keep a log of every call, including the date, the representative's name, and the reference number.
• Ask specifically about the Lilly patient assistance program if you are uninsured or if your Medicaid plan excludes the drug.

For the prescribing clinician:

• Submit the PA with complete documentation from the first attempt. Incomplete submissions are the leading cause of delays.
• Include the most recent HbA1c result, the medication history showing prior agents trialed, a brief clinical narrative, and, if applicable, cardiovascular or renal comorbidity documentation.
• If the patient has a cardiologist or nephrologist, a co-signature or supporting letter from that specialist adds credibility to the request.
• Set a 72-hour follow-up in the practice management system for every tirzepatide PA submission.

The FDA label for Mounjaro states the recommended starting dose is 2.5 mg subcutaneously once weekly for 4 weeks, followed by an increase to 5 mg once weekly, with further increases in 2.5 mg increments possible every 4 weeks as tolerated, up to a maximum of 15 mg weekly [1]. Documenting the planned dose titration schedule in the PA request shows the reviewer a clinically appropriate management plan.